Deerfield Management Company, L.P. (Series C) Novavax Inc Transaction History
Deerfield Management Company, L.P. (Series C)
- $5.38 Billion
- Q3 2024
A detailed history of Deerfield Management Company, L.P. (Series C) transactions in Novavax Inc stock. As of the latest transaction made, Deerfield Management Company, L.P. (Series C) holds 92,597 shares of NVAX stock, worth $805,593. This represents 0.02% of its overall portfolio holdings.
Number of Shares
92,597Holding current value
$805,593% of portfolio
0.02%Shares
1 transactions
Others Institutions Holding NVAX
# of Institutions
290Shares Held
93.4MCall Options Held
6.95MPut Options Held
9.4M-
Vanguard Group Inc Valley Forge, PA15.4MShares$134 Million0.0% of portfolio
-
Black Rock Inc. New York, NY11.8MShares$103 Million0.0% of portfolio
-
Shah Capital Management9.82MShares$85.4 Million40.63% of portfolio
-
State Street Corp Boston, MA7.69MShares$66.9 Million0.0% of portfolio
-
D. E. Shaw & Co., Inc. New York, NY5.94MShares$51.7 Million0.07% of portfolio
About NOVAVAX INC
- Ticker NVAX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 78,215,104
- Market Cap $680M
- Description
- Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; Nan...